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INTRODUCTION
Alzheimer’s disease is the most common subtype of
dementia. This disease is diagnosed in approximately two
thirds of all cases of dementia (1). According to current diag-
nostic criteria, a diagnosis of Alzheimer’s disease is consid-
ered probable when alternative causes of dementia have been
excluded (2, 3). A clinical diagnosis of dementia is often
made according to the Diagnostic and Statistical Manual of
Mental Disorders, Third Edition, Revised (DSM-III-R)
criteria for dementia, with a subdiagnosis of Alzheimer’s
disease made according to the National Institute of Neurolog-
ical and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (2). The pathogenesis of Alzheimer’s
disease is largely unknown. In short, the most frequently used
explanation is that unknown genetic or environmental factors
initiate a cascade of neuropathologic events that feature accu-
mulation of β-amyloid and neurofibrillary tangles. This
process is clinically characterized by a long latent phase, then
a prodromal stage with a gradual and progressive decline in
long-term episodic memory and impairment of other cogni-
tive domains of mental functioning (4). Eventually, the
person crosses a threshold of cognitive loss, after which the
full syndrome is evident (5).
Many patients with Alzheimer’s disease have signs of
cerebrovascular disease on magnetic resonance imaging,
which may contribute to the clinical manifestations of their
dementia. Age, depression, low educational level, athero-
sclerosis, vascular factors (6–8), and smoking (9) are associ-
ated with an increased risk of Alzheimer’s disease. In
addition, a growing number of genetic factors have been
implicated in Alzheimer’s disease, including dominant
mutations (amyloid precursor protein, presenilins 1 and 2)
and susceptibility genes (apolipoprotein E and others under
investigation, such as α2-macroglobulin) (10, 11).
Currently, the goal in managing patients with Alzheimer’s
disease is to maximize cognition and overall functioning,
which involves a combination of strategies that include
education, training, family support, behavioral interventions,
and pharmacotherapy. However, the fact that the pathogen-
esis of Alzheimer’s disease is largely unknown makes it
difficult to develop effective pharmacotherapy. Until
recently, the pharmaceutical industry has focused mainly on
cholinergic agents, since a cholinergic neurotransmitter
deficit has been held partly responsible for cognitive deteri-
oration. The US Food and Drug Administration approved the
drugs tacrine, donepezil hydrochloride, and rivastigmine
(12). Recent progress in delineating the disease cascade has
made it easier to define potential targets for pharmacologic
prevention. This fact is important because, in the long run,
the opportunity to prevent or delay onset of clinically
apparent Alzheimer’s disease is considerably more
appealing than symptomatic therapies that may prolong
illness with only marginal improvement in quality of life.
Therefore, this review focuses on the potential preventive
role of pharmacologic agents in the latent and prodromal
stages of the disease (13) and not on treatment of Alz-
heimer’s disease.
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METHODS
For this review, we searched PUBMED/MEDLINE
(National Institutes of Health, Bethesda, Maryland) until
April 2002 by using the terms “drugs” or “pharmacology” on
the one hand combined with “dementia” or “Alzheimer’s
disease” on the other. We also combined the latter two terms
with all individual drugs mentioned in this review. Further-
more, we scrutinized the Internet and US congressional
material, and we used information from personal communi-
cations with the authors regarding the observational and
experimental studies mentioned in this review, when
possible. We included reviews, data from clinical trials, and
observational studies with a reference group as long as the
results were published in English, French, German, or Dutch
medical journals. Although we included some data from
studies without reference groups, case reports and case series
were excluded. Throughout our review, we gave priority to
well-designed, prospective, double-blind, randomized clin-
ical trials and to prospective cohort studies with incident
cases of Alzheimer’s disease and complete histories of drug
exposure, because they have the highest credibility. Never-
theless, we also covered retrospective case-control studies,
historical cohort studies, and cross-sectional studies.
Because of the importance of prospective, randomized,
double-blind trials, they are discussed under a separate
heading. Furthermore, we divided observational studies into
those with prevalent cases and those with incident cases
because the latter are less vulnerable to bias.
Most drugs currently considered potentially beneficial act
as modulators of neurotransmission, atherosclerosis, or
inflammation. Consequently, we discuss studies on the asso-
ciation between Alzheimer’s disease and 1) nonsteroidal anti-
inflammatory drugs (NSAIDs) and aspirin; 2) glucocorticoids
and other drugs with anti-inflammatory properties; 3) estro-
gens, in the form of hormone replacement therapy (HRT); 4)
histamine 2 (H2)-receptor antagonists; 5) antihypertensive
agents; 6) cholesterol-lowering agents; 7) benzodiazepines;
and 8) free-radical scavengers. Subsequently, in the different
sections of this review for each drug group, we discuss the
putative mechanism by which these drugs might prevent
Alzheimer’s disease and discuss the most relevant studies.
Finally, we systematically summarize and classify the overall
evidence and discuss potential future developments.
EPIDEMIOLOGY OF DRUGS IN THE ONSET OF 
ALZHEIMER’S DISEASE 
NSAIDs and aspirin
Biologic rationale.   NSAIDs are prescribed for a variety of
conditions. Indications for chronic use are (inflammatory)
joint diseases such as rheumatoid arthritis and osteoarthritis
or other systemic diseases. NSAIDs include salicylates,
phenylacetic acid derivatives, propionic acid derivatives,
oxicam derivatives, pyrazolone derivatives, and a small
group of other compounds. Their best-known common char-
acteristic is (non)specific inhibition of cyclooxygenase
(COX): COX-1 and/or COX-2. Strong and compelling evi-
dence now exists that a number of inflammatory mecha-
nisms are intimately involved in the development of
Alzheimer’s disease (14, 15). These mechanisms include
activation of the complement cascade; up-regulation of a
number of acute-phase proteins, cytokines, and chemokines,
and their receptors; and reactive astrogliosis and microgli-
osis. At the very least, this makes it conceivable that
neuroinflammation exacerbates Alzheimer’s disease
pathology. Targeted to the relevant and appropriate neuroin-
flammatory process, anti-inflammatory drugs may be useful
in either delaying onset or slowing the progression of Alz-
heimer’s disease (16). The various biologic activities of
NSAIDs make the precise mechanism of a beneficial effect
uncertain. However, several theories exist regarding how
NSAIDs (and aspirin) could alter this inflammatory course:
the first is inhibition of inflammation per se through either a
COX- or a non-COX-dependent mechanism by directly acti-
vating the peroxisome proliferator-activated receptor-
gamma nuclear transcription factor (17–19). This factor acts
to suppress expression of certain proinflammatory genes (18,
20). Another theory is that NSAIDs interfere in a process
involving postsynaptic signaling events that use the arachi-
donic pathway (21). NSAIDs suppress the action of COXs,
which catalyze synthesis of prostaglandins. The latter have a
role in the postsynaptic signal transduction cascade of cells
with N-methyl D-aspartate–type glutamate receptors. They
may also potentiate glutamatergic transmission by inhibiting
astrocytic reuptake of glutamate. Both mechanisms can
potentiate excitotoxic cell death. Alzheimer’s disease may
also be a consequence of impaired vascular delivery of nutri-
ents to the brain (22). Another suggested mechanism is the
inhibition of local inflammation by blocking induction of
interleukin-1, interleukin-1β, and possibly interleukin-6 (23,
24). Finally, there is recent evidence that a subcategory of
NSAIDs suppresses the formation of amyloid-β42, possibly
through a change in γ-secretase activity, while others do not
(25).
Studies with prevalent cases.   The association of anti-
inflammatory therapy with Alzheimer’s disease has been
studied in a number of ways (table 1). Initial case-control
studies examined the association indirectly by using proxies of
anti-inflammatory drug therapy, such as rheumatoid arthritis,
as the exposure measure (26–34). These studies have been
reviewed extensively elsewhere (35, 36). Results of these
studies were conflicting but also largely incomparable.
In other studies, the association between a history of anti-
inflammatory drug therapy and Alzheimer’s disease was
examined. Several older case-control studies in which use of
analgesics (including acetaminophen) was examined were
also inconclusive (37, 38). Two studies on subjects with a
shared genetic background (twins and siblings) provided
support for a protective role of NSAIDs in Alzheimer’s
disease (39, 40). In both studies, there was evidence that
(long-term) use of NSAIDs significantly reduced the risk of
Alzheimer’s disease. A number of (population-based)
studies on the cross-sectional association between NSAIDs
and prevalent Alzheimer’s disease show an inverse associa-
tion (41–44), with an effect size ranging from 0.4 to 0.6.
Studies with incident cases.   Several incidence studies on
the association between NSAIDs and Alzheimer’s disease
have been published (43, 45–51) (table 1). Some found no
association between NSAIDs use and the risk of Alzheimer’s
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disease (43, 45, 46, 48, 51), whereas others showed a nonsig-
nificant trend toward a reduced risk in persons with a history
of NSAID use (49, 50). The relative risk of Alzheimer’s
disease was assessed among reported users of aspirin or
other NSAIDs during a long-term follow-up in the Baltimore
Longitudinal Study of Aging. The risk of Alzheimer’s
disease decreased with increasing duration of NSAID use.
Among those subjects with 2 or more years of reported
TABLE 1.   Studies on anti-inflammatory drugs
Author(s), year 
(reference no.) Exposure* Exposure source Design Case source Control source
RR†/OR† (95% CI†) or 
probability
Studies of prevalent Alzheimer’s disease
Heyman et al., 1984 
(27)
Arthritis Interview Matched case-
control
Epidemiologic study 
group (n = 40)
Community 1.19 (NS†)
Ever use of 
analgesics
1.23 (NS)
French et al., 1985 
(30)
Arthritis Interview with 
random 
reconfirmation
Matched case-
control
Veterans Administration 
Medical Center (n = 
78)
Hospital and 
nonhospital 
controls
0.62 (0.29, 1.29) 
(hospital controls)
Hay fever 2.75 (0.81, 10.22)
Amaducci et al., 
1986 (37)
Ever use of 
analgesics 
Next of kin Matched case-
control
Consecutive Alzheimer’s 
disease patients of 
seven neurology 
centers (n = 116)
Hospital 1.21 (NS)
Friend 1.0 (NS)
Jenkinson et al., 
1989 (31)
Rheumatoid arthritis Presence of 
rheumatoid 
arthritis according 
to accepted 
criteria
Case-control Consecutive patients of a 
geriatric unit (n = 96)
Consecutive 
patients of 
geriatric unit
0.17 (p < 0.005)
Broe et al., 1990 
(26)
Arthritis Interview Matched case-
control
Clinic based (n = 170) General practitioner 
practice of 
corresponding 
case
0.56 (0.36, 0.87)
Allergies 0.97 (0.60, 1.58)
Graves et al., 1990 
(28)
History of steroid 
use
Telephone 
interviews with 
patients’ and 
controls’ 
surrogates
Matched case-
control
Clinic based (n = 130) Friends and 
nonblood 
relatives
0.73 (0.38, 1.38)
Rheumatoid arthritis 1.18 (0.35, 3.91)
McGeer et al., 1990 
(33)
Rheumatoid arthritis Presence of 
rheumatoid 
arthritis
Incidence 
study
Clinic based (n = 4) None, but 
referenced to the 
Canadian Study 
of Health and 
Aging
2.7% vs. 5.1%
Beard et al., 1991 
(32)
Rheumatoid arthritis Presence of 
rheumatoid 
arthritis
Incidence 
study
Clinic based (n = 23) Reference to other 
clinical population
4.4% vs. 2.7%
McGeer et al., 1992 
(67)
Continuous use of 
dapsone or 
closely related 
agents
Current use Cohort Living leprosy patients in 
Japan (n = 151, all 
dementia)
Living leprosy 
patients in Japan
0.63 (0.43, 0.92)
Li et al., 1992 (29) Arthritis (before 
onset)
Interview of relatives Matched case-
control
Clinic based (n = 70) Registration offices 
in neighborhoods
0.2 (0.06, 0.70)
Analgesics (≥2 
years’ use)
1.0 (0.09, 11.03)
Henderson et al., 
1992 (38)
Analgesics (ever 
daily use for >6 
months)
Interview of an 
informant
Matched case-
control
General practitioner 
practice (n = 170) 
consecutive referrals 
General practitioner 
practice
1.4 (p  = 0.05), 
early onset
0.5 (NS), late onset
Canadian Health 
Study, 1994 (41)
Arthritis Questionnaires 
completed by 
proxy 
respondents
Nested case-
control
Communities and 
institutions (n = 224)
Communities and 
institutions
0.55 (0.37, 0.82)
NSAID† 0.75 (0.39, 1.46)
Steroids 0.54 (0.36, 1.46)
Table continues
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NSAID use, the relative risk was lower than for those who
used NSAIDs for less than 2 years. Overall use of aspirin and
acetaminophen was not associated with Alzheimer’s disease
(47). In a larger and more recent investigation from the
Rotterdam Study, a similar observation was made with
respect to the use of NSAIDs, but not for aspirin (52). Use of
NSAIDs for more than 2 years was associated with an 80
percent risk reduction. This study had the advantage of the
availability of unbiased drug dispensing data and a larger set
of incident cases. As a consequence, misclassification of
TABLE 1.   Continued
Author(s), year 
(reference no.) Exposure* Exposure source Design Case source Control source
RR†/OR† (95% CI†) 
or probability
Breitner et al., 1994 
(39)
Anti-inflammatory 
drugs (use for >1 
year; began >2 
years before 
onset)
 Self-reporting or, if 
not possible, from 
surrogates
Co-twin 
control
Male and female twins 
from the United States
Male and female 
twins from the 
United States
1.0 (0.21, 4.73) 
(male)
0.0 (0.01, 0.43) 
(female)
Breitner et al., 1995 
(40)
NSAID (duration) Interview of 
unaffected 
persons and/or 
collateral 
information
Sibship study Siblings (n = 107) Siblings 0.19 (0.06, 0.64)
Steroids 0.63 (0.12, 2.63)
Aspirin 0.34 (0.14, 0.84)
Rich et al., 1995 
(34)
NSAID daily for 12 
months
Interview Cohort Cohort of Alzheimer’s 
disease patients
NA† Better performance 
on MMSE,† 
Boston Naming 
Test, and others
 
Andersen et al., 
1995 (42)
NSAID (use in past 
week, dose)
Interview of subjects 
and/or proxy 
informants
Population-
based 
cohort 
study
Cohort (n = 339) Population-based 
cohort (total)
0.38 (0.15, 0.95)
Topical medication 
users (subgroup)
0.54 (0.16, 1.78)
Endoh et al., 1999 
(68)
Dapsone, 
rifampicin, 
clofazimine, 
minomycin, or 
ofloxacin
Medical files Cohort Leprosy patients of the 
national leprosarium in 
Tokyo, Japan (n = 35)
Leprosy patients of 
the national 
leprosarium in 
Tokyo, Japan
0.79 (0.53, 1.84)
3.37 (1.87, 5.97), 
<80 years
Anthony et al., 2000 
(44)
NSAID Interview/medicine 
chest inventory
Case-control Cache County, Utah, 
cohort (n = 201)
Cache County, 
Utah, cohort
0.47 (0.24, 0.90)
Studies of incident Alzheimer’s disease
Kukull et al., 1994 
(45)
NSAID (5 years 
prior)
Computerized 
pharmacy data
Case-control Alzheimer’s disease 
patient registry health 
maintenance 
organization (n = 268)
Health maintenance 
organization
Ever 0.8 (0.6, 1.2)
>180 daily doses 1.1 (0.7, 1.8)
Fourrier et al., 1996 
(46)
NSAID use (both at 
baseline and 1 
year later)
Repetitive interviews Prospective 
population-
based 
cohort 
study
Random sample of the 
population of France 
(n = 47)
Random sample of 
the population of 
France
0.98 (0.23, 4.16)
Stewart et al., 1997 
(47)
NSAID (<2 years) Repetitive interviews Nested case-
control in 
the 
Baltimore 
Longitudinal 
Study of 
Aging
Volunteers (n = 81) Volunteers 0.65 (0.33, 1.29)
NSAID (≥2 years) 0.40 (0.19, 0.84)
Aspirin (<2 years) 0.58 (0.28, 1.18)
Aspirin (≥2 years) 0.82 (0.50, 1.36)
Table continues
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exposure was less of a problem. A phenomenon observed in
the Baltimore, Maryland, study; the Rotterdam Study; and a
yet-unpublished study from Cache County, Utah, was that
NSAIDs may offer protection until only a few years before
the actual diagnosis (13).
Studies on NSAIDs are particularly vulnerable to misclas-
sification of exposure. Because NSAIDs are often used peri-
odically and to a different extent by different age groups, it is
difficult to obtain reliable information on exposure. Reliable
and valid data might be particularly difficult to obtain from
proxy interviews (48). Over-the-counter sales may reduce
the validity of medical and pharmacy records as sources of
drug exposure. In general, measurement of exposure has
been a problem to some extent in all follow-up studies on
NSAIDs. In some studies, duration was not taken into
account at all (43, 45, 46, 48, 49, 51). In others, and if
assessed, the methodology used to measure duration of
exposure may have introduced misclassification bias.
Repeated cross-sectional measurements could have led to an
overestimation of drug use (47). In earlier analyses in the
Rotterdam Study, the missing duration of individual
prescriptions was imputed, which might have led to system-
TABLE 1.   Continued
* Exposure or exposure proxied by disease.
† RR, relative risk; OR, odds ratio, CI, confidence interval; NS, nonsignificant; NSAID, nonsteroidal anti-inflammatory drug; NA; not
applicable; MMSE, Mini-Mental State Examination; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale.
Author(s), year 
(reference no.) Exposure* Exposure source Design Case source Control source
RR†/OR† (95% CI†) 
or probability
Henderson et al., 
1997 (48)
NSAID, aspirin Interview Prospective 
cohort study
Community Community NS
Beard et al., 1998 
(49)
NSAID, aspirin for 
≥7 days in the 2 
years before 
onset
Medical records Matched case-
control
Clinic based (n = 302) Clinic 0.47 (0.20, 1.10), 
NSAID
0.90 (0.51, 1.59), 
NSAID + aspirin
Brooks et al., 1998 
(43)
NSAID (current 
use), aspirin
Interview Prospective 
cohort study
Community (8.4% = 53) Community NS
Cornelius et al., 
1998 (51)
NSAID taken 
regularly 
Interview Prospective 
population-
based cohort 
study
Cohort (n = 110) Cohort 0.8 (0.4, 1.9)
in ’t Veld et al., 1998 
(50)
NSAID (in the 10 
years before 
diagnosis)
General 
practitioners’ 
medical 
records
Nested matched 
case-control 
study within the 
Rotterdam 
Study
Cohort (n = 101) Cohort (population 
based)
<2 months 0.76 (0.37, 1.57)
2–6 months 0.97 (0.44, 2.17)
>6 months 0.27 (0.05, 1.51)
in ‘t Veld et al., 2001 
(52)
NSAID (8-year 
follow-up)
Pharmacy filling 
records
Prospective 
population-
based cohort 
study
Cohort (n = 293) Cohort (population 
based)
<1 month 0.95 (0.70, 1.29)
1–24 months 0.83 (0.62, 1.11)
>24 months 0.21 (0.05, 0.83)
Trials
Rogers et al., 1993 
(54)
Randomization to 
placebo or 
indomethacin
NA Placebo-
controlled 
secondary 
prevention trial
Volunteer Alzheimer’s 
disease cases (n = 44)
NA Significantly better 
performance on 
cognitive tests (p 
< 0.003)
Scharf et al., 1999 
(55)
Randomization to 
placebo or 
diclofenac/ 
misoprostol
NA Placebo-
controlled 
secondary 
prevention trial
Volunteer Alzheimer’s 
disease cases (n = 41)
NA Test-battery: no 
significant 
differences in 
intention-to-treat 
analyses
Aisen et al., 2000 
(70)
Randomization to 
placebo or 
prednisone (10 
mg) for 1 year
NA Placebo-
controlled 
secondary 
prevention trial
Volunteer Alzheimer’s 
disease cases (n = 
138) 
NA No difference on 
ADAS-cog† (p = 
0.16)
Behavioral decline in 
treatment group
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atic or random misclassification (50). A problem in almost
all studies was that it was unclear which particular NSAID
was responsible for the risk reductions observed. Further-
more, only a few studies (47, 50, 52) took into account the
timing of intake in relation to time of onset; this difference
may be important given the unknown duration of the latent
and prodromal stages of Alzheimer’s disease.
Finally, confounding by indication and contraindication
may be important. First, pain perception and expression may
be different in those becoming cognitively impaired or in
demented subjects (53). If either pain perception or expres-
sion is impaired in (those developing) Alzheimer’s disease,
this impairment may lead to a lesser use of NSAIDs and an
ostensible protective effect of NSAIDs. In addition, because
of the higher chance of adverse events in cognitively
impaired subjects, physicians may be less likely to prescribe
NSAIDs in the preclinical and clinical phases of Alzheimer’s
disease. On the other hand, prescription behavior may be
influenced by early publications on potential beneficial
effects of NSAIDs.
Clinical trials.   To our knowledge, no primary prevention
trials have been published on anti-inflammatory drugs and
Alzheimer’s disease. A 6-month secondary prevention trial
on indomethacin in Alzheimer’s disease showed that
patients performed significantly better on a battery of cogni-
tive tests after 6 months of therapy compared with placebo
(54). However, a large number of participants reported
adverse effects; consequently, the dropout rate was high.
Currently, an attempt is being made to reproduce these
results in a larger multicenter study in the Netherlands
(unpublished data). The efficacy and safety of diclofenac in
combination with misoprostol were evaluated in 41 patients
with mild-to-moderate Alzheimer’s disease in a prospective,
25-week, randomized, double-blind, placebo-controlled trial
(55). This small pilot study did not demonstrate a significant
effect of NSAID treatment in Alzheimer’s disease but
observed trends that justify further investigations with a
larger number of participants. Before more definite conclu-
sions can be drawn, final results of studies on COX-2 inhib-
itors are awaited (56, 57) but do not appear to be promising
(58). However, it is questionable whether it is valid to
extrapolate findings of these trials to primary prevention.
Therefore, we must await the results from the recently initi-
ated Alzheimer’s Disease Anti-Inflammatory Prevention
Trial (59). This trial, estimated to last for 6 years, is designed
to test naproxen and celecoxib for their ability to prevent
Alzheimer’s disease. The uncertainty regarding the target
mechanism and the absence of a well-accepted model for
Alzheimer’s disease–type neuroinflammation may have
contributed to the decision to treat subjects with either a
selective or a nonselective NSAID.
Studies on aspirin have focused mainly on stroke, showing
a protective effect in secondary prevention (60). Whether
and to what extent this protective effect can be extrapolated
to nonvascular dementia and, in particular, to Alzheimer’s
disease remains to be elucidated.
Glucocorticoids and other anti-inflammatory drugs
Biologic rationale.   Glucocorticoids are used mainly to
treat noninfectious inflammatory systemic diseases and for
chronic obstructive pulmonary disease. These potent anti-
inflammatory/immunosuppressive drugs are also used to
suppress inflammatory processes in the brain. They suppress
acute-phase response neutrophil adherence and monocyte
accumulation as well as inhibit prostaglandin production
(61). However, doses commonly used to suppress secondary
brain inflammation in other diseases are toxic with long-term
treatment and lead to a high incidence of severe adverse
effects such as osteoporosis, behavioral disturbances, and
other problems (62, 63). It has been suggested that glucocor-
ticoids may be toxic to the hippocampus (64, 65), a vital
memory structure. Moreover, postmortem studies in non-
Alzheimer’s subjects suggest that corticosteroids, in contrast
to NSAIDs, do not seem to reduce microglial activation (66).
Studies with prevalent cases.   Thus far, only a few epide-
miologic studies exist on the association between glucocorti-
coid use and Alzheimer’s disease (table 1). In a twin study,
onset of Alzheimer’s disease was inversely associated with
prior concomitant use of corticosteroids or adrenocorti-
cotropin (ACTH) (39). In a larger study of siblings who had
a high risk of Alzheimer’s disease, no significant difference
in risk was found after exposure to glucocorticoids (40). Two
other studies that were considerably larger (28, 41), one of
which was population based (41), did not find a significant
association (table 1). In a review on the role of anti-
inflammatory drugs in Alzheimer’s disease, pooling of data
from the above studies yielded a significant inverse associa-
tion (36).
In a Japanese study on leprosy, the anti-inflammatory/
bacteriostatic agent dapsone (diaphenylsulfone) seemed to
have a protective effect on dementia (67). In a more recent
study from Japan of prevalent Alzheimer’s disease cases, in
which a variety of antileprosy drugs were investigated, this
protective effect was not confirmed (68). In subjects less
than 80 years of age, there was an increased risk of Alz-
heimer’s disease in users.
Clinical trials.   Results from the secondary prevention
Multicenter Trial of Prednisone in Alzheimer’s Disease (69)
have recently become available (70) (table 1). A total of 138
subjects were randomly assigned to receive either placebo or
an initial dose of 20 mg of prednisone, tapered after 4 weeks
to 10 mg and continued for a year. There were no differences
in performance on the cognitive subscale of the Alzheimer’s
Disease Assessment Scale. However, prednisone-treated
subjects showed a behavioral decline compared with the
placebo group.
A trial on the effect of hydroxychloroquine on progression
of Alzheimer’s disease revealed no beneficial effect after 18
months of treatment (71). Finally, colchicine, normally
prescribed for gout, has been proposed as a potential benefi-
cial agent in Alzheimer’s disease (72), and secondary
prevention trials in Alzheimer’s disease have been started.
Where do we stand now with respect to the overall
evidence regarding anti-inflammatory drugs in Alzheimer’s
disease? Given the current research, it seems unlikely that
corticosteroids will be of great benefit in preventing Alz-
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heimer’s disease (70). Although some clinicians already rec-
ommend NSAIDs as a primary or secondary preventive
agent for Alzheimer’s disease and available evidence is
strong and increasing, we do not think that the evidence war-
rants their preventive prescription yet. To draw more definite
conclusions, results from the earlier-mentioned Alzheimer’s
Disease Anti-Inflammatory Prevention Trial and others must
be awaited. In addition, the focus has to be on NSAID groups
with a potential effect on peroxisome proliferator-activated
receptor and amyloid formation.
TABLE 2.   Studies on hormone replacement therapy
Author(s), year 
(reference no.) Exposure Exposure source Design Case source Control source
RR*/OR* (95% CI*) 
or probability
Studies in prevalent Alzheimer’s disease
Heyman et al., 
1984 (27)
Ever HRT* in the 
last 3 months
Interview Matched case-
control
Epidemiologic 
study group 
(n = 28)
Community 2.32 (NS*)
Amaducci et al., 
1986 (37)
Ever HRT Interview next of 
kin
Matched case-
control
Seven centers 
(n = 116)
Hospital/
population
Hospital: 0.71 
(NS)
Population: 1.67 
(NS)
Graves et al., 
1990 (28)
Ever HRT Telephone 
interviews with 
patients’ and 
controls’ 
surrogates
Matched case-
control
Clinic based 
(n = 60)
Friends and 
nonblood 
relatives
1.15 (0.50, 2.64)
Broe et al., 1990 
(26)
Ever HRT Interview Matched case-
control
Clinic based 
(n = 106)
General practice 
of 
corresponding 
case
0.78 (0.39, 1.56)
Henderson et al., 
1994 (90)
Ever HRT Interview 
nondemented 
subjects and 
primary 
Alzheimer’s 
disease 
caregivers 
Case-control Volunteer sample 
of 
consecutively 
enrolled 
women 
(n = 143)
Volunteer sample 
of 
consecutively 
enrolled 
women
0.33 (0.15, 0.74)
Birge, 1994 (88) Current use and 
duration of 
HRT
Interview Matched case-
control
Clinic (n = 158) Clinic 0.07 (p < 0.01)
Mortel and 
Meyer, 1995 
(89)
Ever HRT Medical record/
proxy informant
Case-control 306 subjects 
referred to 
clinic (n = 93)
Friend/relative 0.53 (0.27, 0.94)
Lerner et al., 
1997 (91)
Ever HRT Interview 
nondemented 
subjects and 
primary 
Alzheimer’s 
disease 
caregivers
Case-control Unknown (n = 88) Unknown 0.58 (0.25, 0.91)
Balderischi et al., 
1998 (87)
Ever HRT Interview Population-based 
cohort
8 municipal 
population 
registers 
(n = 92)
8 municipal 
population 
registers
0.28 (0.08, 0.98)
Slooter et al., 
1999 (93)
Ever HRT Interview next of 
kin
Matched case-
control 
All patients with 
early-onset 
Alzheimer’s 
disease in two 
regions of the 
Netherlands 
(n = 109)
Municipal 
population 
register
0.44 (0.21, 0.96)
Studies in incident Alzheimer’s disease
Brenner et al., 
1994 (92)
All HRT before 
onset
Computerized 
pharmacy data 
for a maximum 
of 15 years
Case-control Alzheimer’s 
disease 
registry from 
health plan 
population 
(n = 107)
Stratified random 
sample of 
health plan 
population
1.1 (0.6, 1.8)
Oral HRT before 
onset
0.7 (0.4, 1.5)
Table continues
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HRT
Biologic rationale.   HRT in the form of estrogen (in
combination with progestins) is generally prescribed for
estrogen-dependent perimenopausal complaints and for
preventing and treating osteoporosis. It has been hypothe-
sized that decreasing levels of circulating estrogen after
menopause might increase the risk of Alzheimer’s disease
and that substitution may postpone or even prevent onset of
the disease.
Proposed biologic mechanisms by which estrogen might
attenuate neuronal injury are through direct stimulation of
cholinergic neurons, development of gliacytes, antioxidative
TABLE 2.   Continued
* RR, relative risk; OR, odds ratio; CI, confidence interval; HRT, hormone replacement therapy; NS, nonsignificant; NA, not applicable.
Author(s), year 
(reference no.) Exposure
Exposure 
source
Design Case source Control source RR*/OR* (95% CI*) 
or probability
Paganini-Hill and 
Henderson, 
1996 (111)
HRT for ≤3 years Interview 
(repetitive)
Nested matched 
case-control
Retirement 
community 
(n = 248)
Retirement 
community
0.83 (0.56, 1.22)
HRT for 4–14 
years
0.50 (0.31, 0.81)
HRT for ≥15 
years
0.44 (0.26, 0.75)
Tang et al., 1996 
(96)
HRT for ≤1 year Interview Prospective 
cohort
Medicare 
recipients, 
senior centers, 
and elderly 
housing sites 
(n = 167)
Medicare 
recipients, 
senior centers, 
and elderly 
housing sites
0.47 (0.2, 1.10)
HRT for >1 year 0.13 (0.02, 0.92)
Kawas et al., 
1997 (97)
HRT for >0–5 
years
Repetitive 
interviews
Cohort Community 
volunteers 
(n = 34)
Community 
volunteers
0.44 (0.12, 1.51)
HRT for 5–10 
years
0.34 (0.05, 2.52)
HRT for >10 
years
0.50 (NS)
Waring et al., 
1999 (98) 
HRT for <6 
months
HRT for ≥6 
months 
Review of 
medical 
records
Matched case-
control 
Mayo clinic 
residents of 
Rochester, 
Minnesota 
(n = 222)
Sample from the 
Rochester 
population
0.85 (0.44, 1.62)
0.42 (0.18, 0.96) 
in ‘t Veld et al., 
2000 (99)
HRT for <12 
months
Interview Prospective 
cohort
All new female 
patients from 
population-
based cohort 
(n = 79)
Cohort 0.9 (0.37, 2.21)
HRT for ≥12 
months
1.03 (0.32, 3.30)
Trials
Schneider et al., 
1996 (106)
HRT/tacrine NA* Randomized 
placebo- 
controlled 
secondary 
prevention trial
Multicenter 
(n = 318)
NA Enhancement of 
tacrine effect 
by estrogens
Mulnard et al., 
2000 (106)
Randomization to 
placebo or 
estrogen 
replacement 
therapy (0.625/
1.25 mg) for 1 
year
NA Randomized 
placebo- 
controlled 
secondary 
prevention trial 
in women with 
hysterectomies 
Multicenter 
(n = 120)
NA Clinical Global 
Impression 
Scale 
(p = 0.43)
Henderson et al., 
2000 (101)
Randomization to 
placebo or 
estrogen 
replacement 
therapy (1.25 
mg) for 16 
weeks
NA Randomized 
placebo- 
controlled 
secondary 
prevention trial
Multicenter 
(n = 42)
NA Alzheimer’s 
Disease 
Assessment 
Scale (NS)
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properties, down-regulation of amyloid-β-42 production,
and a decrease in excitotoxicity (73–79). In addition,
estrogen may alter brain activation patterns in postmeno-
pausal women during the performance of verbal memory
functions (80). Finally, estrogen may be involved in the
pathogenesis of Alzheimer’s disease through its role in
vascular disease (81, 82).
Studies with prevalent cases.   Evidence exists that
reduced production of estrogen may be linked to onset of
Alzheimer’s disease. Several studies suggest that proxy
measures of higher levels of exposure to estrogen—a higher
body mass index (83, 84), late age at menopause (85), and
early age at menarche—are inversely associated with the risk
of Alzheimer’s disease. On the other hand, data suggest that
there may be no relation or even an inverse relation between
duration of the reproductive period, a measure of total
natural estrogen exposure, and risk of dementia (86).
Studies relating HRT to the risk of Alzheimer’s disease
have yielded inconsistent results (table 2). Initial case-
control studies showed that estrogen use was inversely asso-
ciated with Alzheimer’s disease (26–28, 37). However, these
studies included limited measures of exposure (ever/recent),
investigated the association in prevalent cases, and were
designed to examine multiple risk factors. Furthermore,
these earlier studies did not adequately control for potential
confounders such as education and age at menopause. In
later case-control studies (87–92), exposure was measured
with relatively unbiased methods, for example, by
abstracting medical records (89). Only two studies (87, 93)
were population based. These latter studies all suggested a
risk reduction of approximately 50 percent.
Studies with incident cases.   In the Leisure World Cohort,
an upper-middle-class elderly population in Leisure World
Laguna Hills, a retirement community in southern Cali-
fornia, information on hormone use by nondemented women
was collected during a baseline interview (94). Alzheimer’s
disease, dementia, or senility was diagnosed on the basis of
death certificates. Estrogen users had a significantly lower
risk of Alzheimer’s disease and associated disorders. The
risk was lowest for those women who used the highest dose
of HRT for the longest period of time (94). An important
limitation of this study is that Alzheimer’s disease cases
were identified on the basis of death certificates, which
underestimate dementia (95).
Other prospective studies are based on clinically assessed
Alzheimer’s disease. In the Manhattan, New York, cohort,
the relative risk of developing Alzheimer’s disease for users
of oral and transdermal estrogen was significantly lower
after adjustment for education, ethnic group, and sample
source but not for other behavioral and medical risk factors.
For women who had used estrogen for longer than a year, the
risk reduction was larger than that for women who had used
HRT for a shorter period of time (96). In this study, partici-
pants were sampled from Medicare recipients, senior
centers, and elderly housing sites. This sampling may have
led to biased estimates if a group with a different risk of
Alzheimer’s disease also had a different chance of receiving
HRT. In a sample of 472 peri- and postmenopausal women
in the Baltimore Longitudinal Study of Aging followed for
up to 16 years, HRT use (45 percent) was prospectively
documented during each visit. Although the number of cases
was small (n = 34), the risk of Alzheimer’s disease in HRT
users was significantly reduced; no effect of duration of
therapy was found (97). A study based on the Mayo Clinic
cohort (Rochester, Minnesota) found a significantly inverse
association between long-term (>6 months) estrogen therapy
and Alzheimer’s disease after adjustment for education and
age at menopause. There was a significant trend of
decreasing risk with increasing duration of use (98). Finally,
an 8-year follow-up study of 3,066 postmenopausal women
from the population-based Rotterdam cohort did not confirm
a protective effect observed earlier in other longitudinal
studies (99). Although the latter study accounted for a
number of potential confounders, it lacked power as a conse-
quence of the low postmenopausal HRT exposure in the
Netherlands.
Clinical trials.   No known published primary prevention
data are available on HRT and Alzheimer’s disease.
However, primary prevention trials are ongoing. The
Women’s Health Initiative Memory Study (100) is a compo-
nent of the National Institutes of Health (Bethesda, Mary-
land)–funded Women’s Health Initiative. This multicenter
trial is designed to test the hypothesis that HRT reduces all-
cause dementia in women aged 65 years or older. This trial is
designed to show a 40 percent risk reduction, and it was
anticipated that more than 7,500 women would be randomly
assigned. Other ongoing investigations are 1) the Women’s
International Study of Long Duration Estrogen for Meno-
pause and 2) the Preventing Postmenopausal Memory Loss
and Alzheimer’s with Replacement Estrogens study (101).
In several small secondary prevention trials, some
evidence exists that estrogen may be beneficial in improving
specific cognitive domains (102–104) and that it modifies
the effect of cholinesterase inhibitors (105). These beneficial
results were not confirmed in a larger, more recent trial, in
which a 16-week treatment did not improve symptoms.
Moreover, in an even longer and larger trial, estrogen
replacement therapy for 1 year did not slow disease progres-
sion or improve global, cognitive, or functional outcomes in
women with mild-to-moderate Alzheimer’s disease (106).
Although there is relatively consistent evidence of a
protective effect of HRT, selection bias is possible in obser-
vational studies in which HRT is used as an exposure factor.
Women taking HRT may be healthier in general (107–109)
and consequently have a reduced risk of Alzheimer’s
disease. Furthermore, a higher educational level and a higher
socioeconomic status are associated with HRT use, both of
which are associated with a reduced risk of Alzheimer’s
disease (110). Selection bias pertaining to HRT users might
arise from increased estrogen-related mortality due to breast
cancer or thrombotic complications. On the other hand, if
HRT has a positive prognostic effect on survival after onset
of Alzheimer’s disease, as suggested by some (94, 111), a
prevalent series of Alzheimer’s disease cases may overrepre-
sent women who use HRT. This possibility would make it
more difficult to find an association if one existed. The need
for caution in interpreting results is highlighted in a large-
scale secondary prevention trial on HRT use and coronary
heart disease (112). This study did not confirm a protective
effect found earlier in a large number of observational
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studies, suggesting the possibility that undetected selection
and observation biases could be responsible for the lowered
risk found previously. On the other hand, the pathologic
substrate and therefore intervention strategies may be
different once clinical disease exists. Other problems not
frequently addressed are the changing prescription habits
and contents of HRT products over time. Today’s HRT prep-
arations contain more progestins (if any) than those
prescribed in the last 20 years and are based on different
types of estrogen. These changes may affect the efficacy of
the drug. In spite of the preventive evidence and biologic
plausibility, there is room for some skepticism; a number of
good observational studies and secondary prevention studies
are negative. For a more definite answer, results from
ongoing primary prevention studies will have to be awaited.
H2-receptor blocking agents
Biologic rationale.   H2-receptor antagonists are frequently
prescribed for duodenal ulcers, reflux esophagitis, or ulcer-
ative lesions caused by the use of NSAIDs. Histamine is a
neurotransmitter in the brain, which has not been clearly
implicated in major diseases. All histaminergic neurons
reside in the posterior hypothalamus and innervate most
brain areas, which is compatible with the idea that histamine
is involved in general central regulatory mechanisms. A
postmortem study in humans suggested that a decrease in
brain histamine levels may contribute to the cognitive
decline occurring in Alzheimer’s disease directly or through
the cholinergic system (113). Furthermore, evidence exists
that H2-receptor antagonists can aggravate the neuronal
damage in the hippocampus caused by ischemia (114).
These latter data seem to be in contrast to the hypothesis that
H2-receptor antagonists may inhibit the cascade leading to
excitotoxic cell death (40).
Studies with prevalent cases.   Until now, we know of
only three studies that have been published; two showed a
risk reduction for H2-receptor antagonists independent of
NSAID exposure (40, 44), and the other found no associa-
tion (115) (table 3). It may be difficult to study the indepen-
dent effect of H2-receptor antagonists because previous
(undetected) NSAID use may induce the prescribing of H2-
receptor antagonists if adverse gastrointestinal effects occur.
Given the current evidence, we think that the most likely
future role of H2-receptor antagonists in the (trials on the)
prevention of Alzheimer’s disease is protection against
NSAID-induced gastrointestinal side effects, although
further studies are needed.
Antihypertensives
Biologic rationale.   Antihypertensives are prescribed
mainly for hypertension but also after myocardial infarction
to prevent the heart from remodeling (particularly angio-
tensin-converting-enzyme inhibitors) and for postmeno-
pausal complaints and chronic pain conditions (clonidine
hydrochloride). Evidence is increasing that hypertension
may contribute to development of cognitive impairment and
dementia (116–119). This possibility logically leads to the
hypothesis that antihypertensive drugs might protect against
development of cognitive dysfunction and dementia. It is
currently unclear whether a protective effect on the brain is
the consequence of the lowering of high blood pressure or
whether other mechanisms are also involved (120). Another
suggested explanation is that some antihypertensives (i.e.,
calcium antagonists) may beneficially influence calcium
homeostasis of neurons, thereby preventing or delaying
onset of Alzheimer’s disease (121).
Studies with incident cases.   There is some evidence of a
beneficial effect of antihypertensive drugs on the risk of
Alzheimer’s disease (table 4). In the population-based Kung-
sholmen study of subjects aged 75 years or older, persons
using antihypertensive medication or diuretic monotherapy
at baseline, compared with nonusers, had a reduced risk of
developing dementia (122). An investigation from the
Rotterdam Study yielded comparable risk estimates for users
of antihypertensive drugs. However, results were significant
for vascular dementia only, not for Alzheimer’s disease
TABLE 3.   Observational studies on histamine 2-receptor blocking agents
* RR, relative risk; OR, odds ratio; CI, confidence interval; H2, histamine 2.
Authors, year 
(reference no.) Exposure Exposure source Design Case source (n°) Control source 
RR*/OR* (95% CI*) 
or probability
Studies of prevalent Alzheimer’s disease
Breitner et al., 
1995 (40)
H2*-receptor 
antagonists 
(duration)
Interview of unaffected 
persons and/or collateral 
information
Sibship study Siblings (n = 107) Siblings 0.2 (0.1, 0.7), 1–12 
months
0.06 (0.0, 0.3), >12 
months
Launer et al., 
1997 (115)
H2-receptor 
antagonists (use in 
the past week, 
dose)
Interview Population-based 
cohort study
Cohort (n = 208) Cohort 1.24 (0.52, 2.98)
Anthony et al., 
2000 (44)
H2-receptor 
antagonists
Interview/medicine chest 
inventory
Case-control Cache County, 
Utah, cohort 
(n = 201)
Cache County, 
Utah, cohort
0.47 (0.24, 0.90)
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(123). Both studies were hampered by a relatively short
follow-up and cross-sectional assessment of drug exposure.
Clinical trials.   Currently, the only known primary preven-
tion trial on the association between antihypertensives use
and the risk of Alzheimer’s disease is the Systolic Hyperten-
sion in Europe Trial (table 4). In this trial of isolated systolic
hypertension (160–219 mmHg), subjects were treated with
nitrendipine, and, if blood pressure was not lowered suffi-
ciently, enalapril and/or hydrochlorothiazide were added.
Results showed that the incidence of dementia was 50
percent lower in the treatment group (121). However, it is
unclear whether this protective effect, if real, was a conse-
quence of the lower blood pressure or of a specific neuropro-
tective effect of calcium channel blockade (120). This was a
small study with a short-term follow-up, which needs to be
replicated.
In a trial on stroke prevention by using thiazide diuretics in
older persons with isolated systolic hypertension, treatment
significantly reduced the risk of stroke but not of cognitive
impairment (124). In a secondary prevention trial, sabelu-
zole, a new benzothiazole derivative (calcium channel
blocker), appeared to exert beneficial effects on memory in
Alzheimer’s disease patients (125). Another secondary
prevention study showed that treatment of hypertension with
captopril did not appear to be hazardous or beneficial to
cognitive function in older people with preexisting cognitive
impairment (126).
It is now clear that both diastolic and systolic hypertension
are associated with increased risk of cardio- and cerebrovas-
cular morbidity and mortality. Because of ethical problems,
it is unlikely that future placebo-controlled primary preven-
tion trials will be initiated. Future trials can only compare
different antihypertensive agents, not the overall effect of
antihypertensive treatment within the current treatment
boundaries. Large and, in particular, long-term prospective,
population-based studies will be needed to study the overall
effect of antihypertensive drugs on Alzheimer’s disease.
However, observational studies on antihypertensives and
Alzheimer’s disease are seriously limited by confounding by
indication and comorbidity. Specific drugs are prescribed
according to degree of severity and comorbidity. Further-
more, this comorbidity is sometimes in itself associated with
the occurrence of Alzheimer’s disease (e.g., cardiac prob-
lems, diabetes mellitus, and stroke) or death as a competing
risk. Another potential problem is that hypertension may
lead to cognitive impairment, which appears to be associated
with less-compliant behavior and exposure misclassification
(127). Despite the possibility of multivariate adjustment, it
may therefore be difficult to determine the actual effect of
antihypertensive drugs. However, in weighing the current
evidence, it is likely that adequate antihypertensive treat-
ment will contribute to the prevention of Alzheimer’s
disease.
Lipid-lowering drugs
Biologic rationale.   Lipid-lowering drugs are prescribed to
treat high (high density lipoprotein) cholesterol levels. The
pathophysiology of Alzheimer’s disease appears to be
related to cholesterol metabolism. Apolipoprotein E type 4 is
a cholesterol transport protein (128, 129) and an important
risk factor for Alzheimer’s disease. Patients carrying an
apolipoprotein E type 4 allele have more cardiovascular
disease and, at least partly because of this disease, a higher
risk of Alzheimer’s disease (130). Cholesterol is also
involved in the biology of β-amyloid, a protein that accumu-
lates in the affected brains of Alzheimer’s disease patients.
Cholesterol increases production of this β-amyloid in some
cells (131).
Studies with prevalent cases.   Studies with prevalent
cases currently provide some evidence of a potential effect
of 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, also called statins (132, 133) (table 5).
However, because of their design, these two database studies
TABLE 4.   Studies on antihypertensives
* RR, relative risk; OR, odds ratio; CI, confidence interval; NA, not applicable.
Authors, year 
(reference no.) Exposure Exposure source Design Case source (n°) Control source 
RR*/OR* (95% CI*) 
or probability
Studies of incident Alzheimer’s disease
Guo et al., 1999 
(122)
Use of antihypertensive in the 
2 weeks before interview
Interview Prospective population-
based cohort study
Community 
cohort 
(n = 204, all 
dementia)
Community 
cohort 
0.7 (0.6, 1.0), all 
antihypertensives
0.6 (0.4, 0.9), diuretics
0.6 (0.3, 1.2), beta-
blockers or calcium 
antagonists
Primary prevention trial
Forette et al., 1998 
(121)
Randomization to placebo or 
nitrendipine (+ enalapril 
and/or hydrochlorothiazide, 
if necessary)
Dispensed in trial Randomized placebo-
controlled trial
People with 
systolic 
hypertension 
(n = 23)
NA* p = 0.05, 50% lower 
risk
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suffer from the usual methodological problems in prevalence
studies. In particular, the relatively short availability of this
drug class investigated in subjects with prevalent Alz-
heimer’s disease (which may have lasted for over 10 years)
makes the suggested risk reduction, at the least, less valid.
Another problem in both studies is the lack of uniformity of
the diagnosis of Alzheimer’s disease and the potential of
underascertainment of Alzheimer’s disease. Furthermore,
there is the possibility of differential prescription behavior
with respect to the relatively new class of HMG-CoA reduc-
tase inhibitors over age classes and socioeconomic status for
which these studies cannot adjust.
Clinical trials.   To our knowledge, the Prospective Study
of Pravastatin in the Elderly at Risk is currently the only trial
that looks into the effect of HMG-CoA reductase inhibitors
and the occurrence of cognitive deterioration (134). The
study, which will end in 2002, has included 5,804 subjects
followed for a mean of 3.5 years regarding a number of
endpoints. Until results are available, the evidence is insuffi-
cient to warrant any preventive prescription for Alzheimer’s
disease (135). However, because hypercholesterolemia
causes vascular disease and this vascular disease appears to
contribute to development of Alzheimer’s disease, it is likely
that these lipid-lowering drugs will be implemented as a
preventive agent once the Prospective Study of Pravastatin
in the Elderly at Risk trial suggests a protective effect on
cognitive deterioration.
Benzodiazepines
Biologic rationale.   Benzodiazepines are among the most
frequently prescribed drugs in the elderly. Their clinical appli-
cations include administration as sedatives-hypnotics, anti-
convulsants, and anxiolytics. In animal models of cerebral
ischemia, the inhibitory neurotransmitter γ-aminobutyric acid
(GABA) and GABA-mimetic drugs (benzodiazepines) have
been reported to protect against neuronal damage (136–140).
Benzodiazepines may protect neurons by reducing cerebral
oxygen demand via a reduction in synaptic transmission
(141). A multicenter study on risk factors for incident cogni-
tive dysfunction after operations performed under general
anesthesia was indeed suggestive for a preventive effect of
benzodiazepines started prior to the operation (142). On the
other hand, a large number of experimental studies are avail-
able on the potential (short-term) reversible adverse effects of
benzodiazepines on memory performance (143–148).
However, very little is known about the cognitive effects of
chronic benzodiazepine exposure.
Studies with prevalent cases.   To our knowledge, studies
with prevalent cases on the association of benzodiazepines
and Alzheimer’s disease are not available (table 6). This lack
may reflect the fact that benzodiazepines are often prescribed
for behavioral and sleeping problems related to Alzheimer’s
disease, making it impossible to study associations.
Studies with incident cases.   The relation between chronic
use of benzodiazepines and incident dementia was examined
in the Kungsholmen Study (149) (table 6). Users of benzodi-
TABLE 5.   Studies on lipid-lowering agents
* RR, relative risk; OR, odds ratio; CI, confidence interval; HMG-CoA-RI, 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Authors, year 
(reference no.) Exposure Exposure source Design Case source Control source 
RR*/OR* (95% CI*) 
or probability
Studies of prevalent Alzheimer’s disease
Wolozin et al., 
2000 (132) 
Current use of 
HMG-CoA-RI*
Hospital 
database
Cross-sectional Three hospital 
databases
Total patient 
population 
using at least 
eight drugs
Prevalence lower 
for lovastatin 
and/or 
pravastatin, but 
not 
simvastatin, 
users 
compared with 
controls
Jick et al., 2000 
(133)
Current use of 
HMG-CoA-RI
General Practice 
Research 
Database 
Nested case-
control
Sample from the 
General Practice 
Research 
Database 
(n = 284)
General Practice 
Research 
Database 
0.29 (0.13, 0.63)
Nonstatin lipid-
lowering 
agents
0.96 (0.47, 1.97)
TABLE 6.   Studies on benzodiazepines
Authors, year 
(reference no.) Exposure Exposure source Design Case source Control source Probability
Studies of incident Alzheimer’s disease
Fastbom et al., 
1998 (149)
Benzodiazepines 
(regular)
Interview Prospective population-
based cohort study
Cohort (n = 33) Cohort p = 0.012 (all 
benzodiazepines)
p = 0.013 (hypnotics)
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azepines at both baseline and follow-up had a lower incidence
of Alzheimer’s disease compared with nonusers, after adjust-
ment for age, sex, education, and use of NSAIDs and estrogen.
Because this is probably the first study on the association,
other studies are needed before any conclusion can be drawn.
A potential threat to the validity of studies relating benzodiaz-
epines to Alzheimer’s disease is that preclinical symptoms in
Alzheimer’s disease, such as sleeping problems, may be treat-
ed with benzodiazepines, although such a bias would tend to
overestimate the risk.
Free-radical scavengers
Biologic rationale.   Oxidative stress may play an impor-
tant etiologic role in Alzheimer’s disease (150, 151). Free-
radical scavengers are agents that sequester free radicals so
they do not initiate oxidative reactions that can lead to
cellular damage. These free-radical scavengers can be natu-
rally occurring substances (beta-carotene, vitamins C and E,
estrogen (152, 153), and Ginkgo biloba) or synthetically
prepared substances (selegiline, a monoamine oxidase–B
inhibitor established in the therapy of Parkinson’s disease;
lazabemide, another more selective monoamine oxidase–B
inhibitor (154, 155); and tenilsetam, thought to be an
advanced glycation end-products inhibitor (156)).
Studies with incident cases.   Observational data on free-
radical scavengers and the risk of Alzheimer’s disease are
limited (table 7). We are not aware of studies with prevalent
cases, but there are some with incident cases. In an analysis
of data from the Rotterdam Study that included 58 subjects
with incident dementia, dietary intake of antioxidants was
not associated with a reduced incidence of dementia (152)
(table 7). Observational data on the use of vitamin E and
vitamin C supplements and incident Alzheimer’s disease
have been reported in one study (153). In this prospective
study of 633 persons aged 65 years or older, a stratified
random sample was selected from a disease-free population.
At baseline, all vitamin supplements taken in the previous 2
weeks were identified by direct inspection. After an average
follow-up of 4.3 years, 91 of the sample participants for
whom vitamin information was available met accepted
criteria for the clinical diagnosis of Alzheimer’s disease.
These study data suggest an inverse association between
high vitamin E and vitamin C intakes and Alzheimer’s
disease. However, further exploration is needed; this is prob-
ably the first longitudinal study, and results were significant
for vitamin C only.
One of the reasons for the scarcity of observational studies
may be the complicated assessment of exposure: some anti-
oxidants are in the form of over-the-counter supplements,
herbs, or food. High over-the-counter sales mean that
medical or pharmacy records do not provide a valid measure
of intake. In addition, similar to the use of HRT, the healthy-
user effect may hamper valid assessments.
Clinical trials.   Ginkgo biloba (157–160), selegiline, or α-
tocopherol (vitamin E) and thiamine (vitamin B1) (161) have
been studied as secondary protective agents against Alz-
heimer’s disease (162). The largest known Ginkgo biloba
trial published thus far, in which primary outcome measures
included the Alzheimer’s Disease Assessment Scale-cogni-
tive subscale, the Geriatric Evaluation by Relative’s Rating
Instrument, and the Clinical Global Impression of Change,
showed the superiority of Ginkgo biloba extract over pla-
cebo. In comparison to the baseline values, the placebo
group worsened statistically significantly regarding all
domains of assessment, whereas the group receiving Ginkgo
biloba extract was considered slightly improved with regard
to cognitive assessment and to daily living and social behav-
ior. Regarding the safety of Ginkgo biloba, no differences
were observed (159). However, not all studies confirm these
positive findings (163). The recently started Ginkgo Evalua-
tion of Memory Study may resolve the question as to
whether these findings can be extrapolated to primary pre-
vention.
The selegiline/α-tocopherol trial showed that, in patients
with moderately severe impairment from Alzheimer’s disease,
treatment with selegiline or α-tocopherol slowed progression
of the disease. A potential limitation of this trial is that
progression was defined as a nonspecific outcome that
included time until institutional placement, loss of ability to
perform basic activities of daily living, or severe dementia or
death. There were no significant differences in any of the
cognitive test scores. Furthermore, selegiline may act as an
antidepressant, which could lead to improved cognition.
Results of trials with lazabemide (a monoamine oxidase–B
inhibitor) (155) and N-acetylcysteine (164) must be awaited.
Fewer than 50 people were included in the studies of thiamine,
and the reported results are inadequate (161).
That vitamins and food supplements are popular substances
for intervention studies is suggested by the fact that a vitamin
E primary prevention trial, despite the absence of convincing
evidence (165), received a grant from the National Institutes
of Health. On the other hand, given methodological difficul-
ties, studying this type of substance is the only way to obtain a
reliable answer.
Recent research has increasingly suggested a central role for
free-radical–induced tissue damage in the pathogenesis of
Alzheimer’s disease. In this review, we assess evidence for the
interaction between free radicals and other major factors/
metabolic areas that have also been implicated in Alzheimer’s
disease, including beta-amyloidosis, inflammatory cytokines,
mitochondrial dysfunction, and metal ions/homocysteine.
Free radicals and antioxidants should not be considered in
isolation in the etiology and treatment of Alzheimer’s disease.
It is the reciprocal induction and self-amplifying interplay
between the above factors that is important in the pathogenesis
of this disorder and to which multipharmacologic therapeutic
strategies could be directed. Although some tend to think
otherwise, we feel that, although some evidence exists in favor
of the use of antioxidative substances in preventing Alz-
heimer’s disease, their use is not yet advised.
DISCUSSION
Literature is abundant on the association between drugs
and prevention of Alzheimer’s disease. In view of the scar-
city of well-designed clinical trials, most of the current
epidemiologic knowledge comes from observational
studies. Such studies have potential limitations that may
jeopardize the validity of the results. Before we present the
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overall results of this review, we must discuss these poten-
tial limitations.
Methodological considerations
Prevalent or incident cases.   For methodological reasons,
we distinguished between observational studies with preva-
lent cases and those with incident cases. An obvious problem
with prevalent cases is that it is usually unclear how long
cognitive impairment exists, whether drug use preceded the
onset of Alzheimer’s disease, and, if so, for how long. Most
potential sources of bias may play a role in studies with prev-
alent cases but can be dealt with satisfactorily in prospective
population-based cohort studies by regularly assessing
cognitive function and incident case enrollment. Addition-
ally, restricted analyses of the effects of drug exposure in
such studies, after subtracting the assumed latent period
between onset of cognitive impairment and date of diagnosis
of Alzheimer’s disease (“lagging”), may add further infor-
mation and increase validity (166–168). Therefore, for every
drug (group), this review distinguished between studies
including patients with prevalent Alzheimer’s disease and
studies focusing on incident cases of Alzheimer’s disease,
discussing potential weaknesses. However, even some very
TABLE 7.   Studies on radical scavengers and antioxidants
* RR, relative risk; OR, odds ratio; CI, confidence interval; EGb 761, Ginkgo biloba special extract 761; NA, not applicable; NAB, Nurnberger-
Alters-Beobachtungsskala; CGI, Clinical Global Impression of Change; IADL, Instrumental Activities of Daily Living; SKT-test, psychomimetric
test for attention and memory; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; GERRI, Geriatric Evaluation by
Relative’s Rating Instrument.
Authors, year 
(reference no.) Exposure Exposure information Design Case source Control source 
RR*/OR* (95% CI*)
 or probability
Studies of prevalent Alzheimer’s disease
Broe et al., 1990 
(26)
Vitamin E by 
proxy 
informants
Interview Case-control 
study
General practice 
(n = 170)
General practice 1.3 (0.6, 1.65), 
vitamin E
1.17 (0.5, 2.5), iron
Studies of incident Alzheimer’s disease
Morris et al., 1998 
(153)
Vitamins C and E 
taken in the 
previous 2 
weeks
Interview with 
direct 
inspection
Prospective 
cohort study
Stratified sample 
of cohort of 
disease-free 
subjects 
(n = 91)
Stratified sample 
of cohort of 
disease-free 
subjects
p = 0.10, vitamin C
p = 0.04, vitamin E
Launer and 
Kalmijn, 1998 
(152)
Antioxidants Food 
questionnaire 
interview
Prospective 
population-
based cohort 
study
Cohort (n = 58) Cohort No reduction
Trials
Haase et al., 
1996 (160)
EGb 761* 
intravenous 4 
days per week 
for 4 weeks
NA* Randomized 
double-blind 
secondary 
prevention trial
(Alzheimer, 
vascular 
dementia, or 
mixed type)
NA p = 0.05, NAB* 
p = 0.05, CGI* 
IADL*
Maurer et al., 
1997 (158)
EGb 761 oral 240 
mg per day 
NA Randomized 
double-blind 
parallel group 
design
20 outpatients 
with 
Alzheimer’s 
disease
NA p < 0.013, SKT-
test*
ADAS-cog* (NS*)
Sano et al., 1997 
(162)
Selegiline (10 
mg) and/or α-
tocopherol 
(2,000 IU)
NA Randomized 
double-blind 
secondary 
prevention trial
23 centers 
(n = 341)
NA Significant delay 
until institutional-
ization for treat-
ment group
Le Bars et al., 
2000 (159)
EGb 761 40 mg 
three times a 
day 
NA Randomized 
double-blind 
secondary 
prevention trial
Multicenter 
(n = 309)
NA p = 0.04, ADAS-
cog 
(Alzheimer, 
vascular 
dementia)
p = 0.007, GERRI* 
CGI
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well designed prospective cohort studies with incident case
collection use drug exposure data from a baseline interview.
Such cross-sectional drug assessment as an approximation of
chronic use may lead to nondifferential misclassification of
exposure and a bias toward the zero hypothesis, sometimes
even to differential misclassification of chronic use (169).
Therefore, the best observational prospective cohort studies
are those with continuous registration of drug use, for
instance, by reimbursement or automated pharmacy data
and, if possible, a compliance parameter.
Selection bias, information bias, and confounding.   Several
sources of bias are important in interpreting epidemiologic
studies on the association between drugs and Alzheimer’s
disease (35). Bias is generally divided into selection bias,
information bias, and confounding. Some of these types of
bias may be particularly important in studies on drugs in
Alzheimer’s disease.
Selection bias may occur when selection of subjects for the
drug exposure group and the reference group of a cohort
study differs between Alzheimer’s patients and nondiseased
persons. Similarly, selection of cases and controls in a case-
control study may be different and may depend on exposure
status. Elderly with painful osteoarthritis and with adequate
cognitive function might be more successful than severely
demented persons in communicating their complaints to
their caretakers or in contacting their prescribing physicians.
In this instance, use of NSAIDs could be spuriously associ-
ated with a protective effect. Selection bias may also occur if
cases and controls are drawn from different source popula-
tions (170, 171). For example, studies based on cases
referred to health services may be subject to selection bias if
cases and controls differentially use one type of health
service over another (172). Another example of potential
selection bias is when elderly women with normal cognitive
function use HRT more readily than do women with Alz-
heimer’s disease because news media make the former
aware of the potentially protective effects of estrogens. This
possibility would tend to bias the relative risk toward a pro-
tective effect or exaggerate a true protective effect. The large
majority of these problems can be overcome by using a pro-
spective population-based study design.
Information bias may occur if classification of disease
status depends on exposure status, or vice versa. Of major
concern in observational studies of Alzheimer’s disease is
the potential for misclassification of exposure to drugs
because patients experiencing cognitive decline have
impaired recall. Another potential source of misclassifica-
tion is information from proxy informants. Proxy informants
such as spouses, relatives, or other caregivers of demented
persons may supply exposure information that differs from
the exposure information obtained from proxies of persons
whose cognitive function is normal. Some evidence exists
that information with respect to dramatic exposures is
reported reliably by proxy informants. However, this finding
does not appear to be true for drug use (173), particularly not
when it comes to more detailed aspects such as drug types,
duration of use, and dosage. Furthermore, for over-the-
counter drugs, this method has been reported to be highly
unreliable for exposure classification (174). In addition, use
of this type of information has been reported to lead to bias
due to differential nonresponse or even differential misclas-
sification (169). Another difficulty is the degree of compli-
ance of each person, because it has been shown that even in
nondemented subjects, cognitive function is a determinant of
compliance (175).
Confounding by independent risk factors for Alzheimer’s
disease, such as socioeconomic status or education, which
may also be associated with drug use, can usually be dealt
with in the analyses of observational studies. A conceptually
more difficult type of confounding is confounding by indica-
tion (176, 177). This type occurs when a particular indication
for a certain drug is also a direct risk factor for Alzheimer’s
disease. However, because not many indications for drug use
are known to be direct risk factors for Alzheimer’s disease,
confounding by indication will usually be less of a problem.
This situation is different with vascular dementia, in which
antihypertensives and other cardiovascular drugs may erro-
neously be associated with a risk increase as a result of
confounding by indication (52). 
Conclusions
In recent years, progress has been made in unraveling
presumed protective effects of drugs used in Alzheimer’s
disease. Despite this progress, hardly any effective therapy is
available. Even those clinical trials demonstrating a benefi-
cial effect of the cholinesterase inhibitor rivastigmine
suggest only a modest effect on the three hallmarks of Alz-
heimer’s disease: impaired cognition, changed behavior,
and inability to perform daily activities (178). The data
from our review do not suggest that there is a highly effec-
tive treatment among the currently used pharmacologic
agents, but at least some of them deserve further study.
In view of the scarcity of primary prevention trials, obser-
vational population-based studies can contribute to current
knowledge on the pharmacologic prevention of Alzheimer’s
disease. Our review addressed several general methodolog-
ical problems encountered in such epidemiologic research
on drug effects and Alzheimer’s disease. When studying
drug effects, an adequate definition of exposure is needed,
one that provides details about when the drug was used rela-
tive to onset of the disease, at what dose, and for how long.
Currently, however, both the definition and the assessment
of drug use are imprecise and lack uniformity. Standardiza-
tion of criteria to define Alzheimer’s disease would also
increase the ability to compare studies in a useful way.
Although National Institute of Neurological and Communi-
cative Disorders and Stroke–Alzheimer’s Disease and
Related Disorders Association criteria are frequently used,
use of different diagnostic criteria in the remainder may lead
to very different case populations (179) and potentially to
risk estimates that are difficult to compare. The time of first
clinical symptoms should be well documented; for obvious
reasons, exposure can be preventive only if it occurs before
the disease does. Even if a drug is not preventive but slows
the development of Alzheimer’s disease, precise temporal
relations are needed to judge the association. Unfortunately,
such details are often difficult to obtain.
What can we conclude from the medical literature
included in this review, taking into account all methodolog-
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ical issues? Mainly, evidence for a protective effect on
Alzheimer’s disease is strongest for NSAIDs and HRT. In
addition to reviews, based mainly on studies on prevalent
Alzheimer’s disease (36), several high-quality prospective
studies now support a primary preventive role for (certain)
NSAIDs in Alzheimer’s disease. However, given the high
percentage of potential adverse effects of NSAIDs (54, 180),
their role in primary or secondary prevention of Alzheimer’s
disease is far from clear-cut. It is possible that positive
results from the Alzheimer’s Disease Anti-Inflammatory
Prevention Trial or other pharmaceutical trials, as well as
development of more selective COX-2 inhibitors or of nitric
oxide-releasing (181, 182) or amyloid-specific NSAIDs,
may change this situation. A protective effect was also
consistently demonstrated for long-term use of HRT,
although only two thirds of the studies have been positive. A
meta-analysis comprising the large majority of these studies
also confirmed a protective effect. Because of (suggested)
beneficial effects on postmenopausal complaints, osteo-
porosis (183, 184), and atherosclerosis (82, 185), HRT use is
currently increasing in western countries. If a beneficial
effect of HRT in Alzheimer’s disease is demonstrated in
(ongoing) clinical trials, the benefits may be considered so
large that, in spite of the increased risk of venous throm-
boembolism (112) and breast cancer (186), its use may
increase further, a development that will be strengthened if
selective estrogen receptor modulators, a new class of
synthetic estrogens, really prove to retain beneficial estro-
genic effects in the brain without exhibiting the adverse
effects of HRT (187, 188).
Evidence with regard to a protective effect on Alzheimer’s
disease of corticosteroids, aspirin, H2-receptor antagonists,
and free-radical scavengers is highly inconsistent. This
evidence is slightly better for antihypertensives and benzodi-
azepines, although it is unlikely that the latter will ever be
introduced as primary preventive agents because of the high
risk of addiction, short-term memory problems, and a higher
risk of fractures and accidents. Studies on a protective effect
of antihypertensive therapy on Alzheimer’s disease are
promising, but scanty, and methodologically insufficient.
The evidence of a causal involvement of high blood pressure
is firm, however. Research on the role of antihypertensives
in Alzheimer’s disease should probably focus on the poten-
tial mechanism and thus on the question of whether a protec-
tive effect, if present, is explained solely by lowering of
blood pressure. Because of beneficial effects in cardiovas-
cular and cerebrovascular disease in general, when proven
effective in Alzheimer’s disease, it is likely that treatment
with antihypertensive drugs will be further intensified.
In conclusion, data from observational studies are helpful
as long as we know little about potentially protective drug
effects in Alzheimer’s disease. For the future, placebo-
controlled trials for primary prevention are essential. In light
of the currently developing large-scale efforts regarding
HRT, NSAIDs, HMG-CoA reductase-inhibiting statins,
vitamin E, and Ginkgo biloba, it may prove possible to study
most of the suggested hypotheses mentioned in this review.
In the meantime, available observational data should be
explored further. In particular, prospective, population-
based cohort studies with incident case enrollment, geno-
typing, and adequate and continuous gathering of data on
drug use may be important tools to gain more insight into
potential agents to treat a disease from which so many people
suffer and for which so little therapy is available.
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